The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
A phase II, randomized, double‐blind, placebo‐controlled study evaluating the efficacy and safety of MDX‐1100, a fully human anti‐CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis
Abstract
Objective: CXCL10 (also known as interferon‐γ–inducible 10‐kd protein [IP‐10]) is a chemokine that potentially plays a role in the immunopathogenesis of rheumatoid arthritis (RA). We undertook this phase II study to evaluate the efficacy and safety of MDX‐1100, a fully human, anti‐CXCL10 (anti–IP‐10) monoclonal antibody, in RA patients whose disease responded inadequately to methotrexate (MTX). Methods: Patients with active RA receiving stable doses of MTX (10–25 mg weekly) were randomized to receive intravenous doses of 10 mg/kg MDX‐1100 (n = 35) or placebo (n = 35) every other week. The primary end point was the proportion of patients meeting the American College of Rheumatology 20% improvement criteria (achieving an ACR20 response) on day 85, and patients were followed up for safety to day 141. Results: The ACR20 response rate was significantly higher among MDX‐1100–treated patients than among placebo‐treated patients (54% versus 17%; P = 0.0024). Statistically significant differences in the ACR20 response rate between treatments were observed starting on day 43 (P < 0.05). The ACR50 and ACR70 response rates on day 85 did not differ between the groups. Overall, 51.4% of MDX‐1100–treated patients and 30.3% of placebo‐treated patients experienced at least 1 adverse event (AE). No study drug–related serious AEs were reported. Conclusion: MDX‐1100 was well tolerated and demonstrated clinical efficacy in RA patients whose disease responded inadequately to MTX. This is the first study to demonstrate clinical efficacy of a chemokine inhibitor in RA and supports the notion of a potential role of IP‐10 in the immunopathogenesis of RA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Qin, S., Rottman, J. B., Myers, P., Kassam, N., Weinblatt, M., Loetscher, M., Koch, A. E., Moser, B., & Mackay, C. R. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1422 · Cited by 1,359
Cited by
Bachelerie, F., Ben-Baruch, A., Burkhardt, A. M., Combadiere, C., Farber, J. M., Graham, G. J., Horuk, R., Sparre-Ulrich, A. H., Locati, M., Luster, A. D., et al. (2014) · Pharmacological Reviews · doi:10.1124/pr.113.007724 · Cited by 850
Chemokine (C–X–C motif) ligand (CXCL)10 in autoimmune diseases
Antonelli, A., Ferrari, S. M., Giuggioli, D., Ferrannini, E., Ferri, C., & Fallahi, P. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2013.10.010 · Cited by 595
Mechanisms of joint destruction in rheumatoid arthritis — immune cell–fibroblast–bone interactions
Komatsu, N., & Takayanagi, H. (2022) · Nature Reviews Rheumatology · doi:10.1038/s41584-022-00793-5 · Cited by 527
Promising Therapeutic Targets for Treatment of Rheumatoid Arthritis
Huang, J., Fu, X., Chen, X., Li, Z., Huang, Y., & Liang, C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.686155 · Cited by 340
CXCR3 ligands in disease and therapy
Van Raemdonck, K., Van den Steen, P. E., Liekens, S., Van Damme, J., & Struyf, S. (2015) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2014.11.009 · Cited by 310
Metadata
- Authors
- Yellin, M., Paliienko, I., Balanescu, A., Ter‐Vartanian, S., Tseluyko, V., Xu, L., Tao, X., Cardarelli, P. M., LeBlanc, H., Nichol, G., Ancuta, C., Chirieac, R., & Luo, A.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2012-05-25
- Volume
- 64
- Issue
- 6
- Pages
- 1730-1739
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2066668597
- Cited by
- 194
- References
- 1
- FWCI
- 8.74
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A phase II, randomized, double‐blind, placebo‐controlled study evaluating the efficacy and safety of MDX‐1100, a fully human anti‐CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis. https://app.cochat.ai/papers/10.1002/art.34330
- The paper
- Yellin, M., Paliienko, I., Balanescu, A., Ter‐Vartanian, S., Tseluyko, V., Xu, L., Tao, X., Cardarelli, P. M., LeBlanc, H., Nichol, G., Ancuta, C., Chirieac, R., & Luo, A. (2012). A phase II, randomized, double‐blind, placebo‐controlled study evaluating the efficacy and safety of MDX‐1100, a fully human anti‐CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis. Arthritis & Rheumatism. https://doi.org/10.1002/art.34330
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.